We aspire to transform the metastatic breast cancer treatment paradigm with our therapies. It’s an ambitious endeavor and requires a resolute approach to building our culture – one that’s rooted in our past, informed by our present, inspired by our future, guided by our values, and shaped by our behavior.

Olema was founded on the idea that there’s a better way to deprive breast cancer cells of the estrogen-derived drive to grow and multiply. In the early days of the company, our scientists developed a deep understanding of what constitutes a superior CERAN: the right balance of potency, estrogen antagonism, drug exposure, and combinability. It required years of iteration and effort to discover a superior compound to advance into late pre-clinical development. Years of refining our chemistry, biology, in vivo pharmacology, and scale-up. Years of days and nights at the bench, going above and beyond to produce the molecule that ultimately moved into the clinic and became our lead asset, palazestrant.

Years later, our scientists employed the same rigor in the discovery and development of our newest product candidate, OP-3136 – and it’s the same spirit and passion that propels Team Olema forward today.